

1 TITLE:

2 Emerging genetic diversity of SARS-CoV-2 RNA dependent RNA polymerase (RdRp) alters  
3 its B-cell epitopes.

4

5 AUTHORS:

6 Sushant Kumar<sup>1</sup> and Gajendra Kumar Azad<sup>1#</sup>

7

8 AFFILIATIONS:

9 <sup>1</sup>Department of Zoology, Patna University, Patna-800005, Bihar, India

10 #Corresponding Author: Gajendra Kumar Azad

11 Email address: [gkazad@patnauniversity.ac.in](mailto:gkazad@patnauniversity.ac.in)

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38 ABSTRACT

39 The RNA dependent RNA polymerase (RdRp) plays crucial role in virus life cycle by  
40 replicating the viral RNA genome. The SARS-CoV-2 is an RNA virus that rapidly spread  
41 worldwide and during this process acquired mutations. This study was carried out to identify  
42 mutations in RdRp as the SARS-CoV-2 spread in India. We compared the 668 RdRp  
43 sequences reported from India with the first reported RdRp sequence from Wuhan, China.  
44 Our data revealed that RdRp have acquired sixty mutations among Indian isolates. Our  
45 protein modelling study also revealed that several mutants including D833Y, A699S, Y149C  
46 and C464F can potentially alter stability and flexibility of RdRp. We also predicted the  
47 potential B cell epitopes contributed by RdRp and identified thirty-six linear continuous and  
48 twenty-five discontinuous epitopes. Among sixty RdRp mutants identified in this study, 40%  
49 of them localises in the B cell epitopes region. Altogether, this study highlights the need to  
50 identify and characterize the variations in RdRp to understand the impact of these mutations  
51 on SARS-CoV-2.

52

53 KEYWORDS: COVID-19; SARS-CoV-2; Mutations; B cell epitopes; RNA dependent RNA  
54 polymerase (RdRp); India

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75 INTRODUCTION

76 SARS-CoV-2 genome encodes 29 protein molecules which are categorised into three  
77 groups including structural, non-structural and accessory proteins (Gordon et al., 2020).  
78 SARS-CoV-2 has four structural proteins namely Spike glycoprotein, Membrane protein,  
79 Envelope protein and Nucleocapsid Phosphoprotein (Wu et al., 2020). It also encodes  
80 sixteen non-structural proteins (Nsp1-16) and nine accessory proteins (Chan et al., 2020).  
81 The non-structural proteins are involved in the maintenance of its genome, virulence and  
82 important steps of virus life cycle. The 16 non-structural proteins are synthesised as a single  
83 polypeptide molecule of 7096 amino acids known as Orf1ab that is subsequently cleaved  
84 into 16 separate proteins (Chan et al., 2020). The RNA dependent RNA polymerase (RdRp),  
85 also known as Nsp12, is a non-structural protein that replicates SARS-CoV-2 RNA genome  
86 (Wu et al., 2020). It associates with Nsp7 and Nsp8 and exist as a trimeric complex inside  
87 the viral envelope structure (Peng et al., 2020). By itself, RdRp has a very weak polymerase  
88 activity; however, the complex of RdRp with Nsp7 and Nsp8 significantly increases RdRp  
89 processivity and template affinity (Te Velthuis et al., 2012; Zhai et al., 2005).

90 RdRp of SARS-CoV-2 is 932 residues in length and contains distinct polymerase and  
91 nucleotide binding domains with a central connecting domain (Gao et al., 2020). Structurally,  
92 RdRp is comprised of an N-terminal  $\beta$ -hairpin (residues 31-50) followed by an extended  
93 nidovirus RdRp-associated nucleotidyl-transferase domain (NiRAN, residues 115-250) (Yin  
94 et al., 2020). Following the NiRAN domain is an interface domain (residues 251-365)  
95 connected to the RdRp domain (residues 366-920). Further, the domains of RdRp arranges  
96 in such a way that it forms a canonical right-handed cup configuration (Mcdonald, 2013),  
97 with the finger subdomain (resides 397-581 and residues 621-679) forming a closed circle  
98 with the thumb subdomain (residues 819-920)(Yin et al., 2020).

99 The SARS-CoV-2 was first reported from Wuhan province China in late 2019 (Wu et al.,  
100 2020). Wet sea food market area of Wuhan reported patients with pneumonia like  
101 symptoms, which was later identified as SARS-CoV-2 because of its similarity with SARS-  
102 CoV (Gorbalenya et al., 2020). The SARS-CoV-2 is highly contagious and causes mild to  
103 severe respiratory distress in infected individuals and the disease has been named as  
104 COVID-19 (World Health Organization, 2020). The SARS-CoV-2 spread very fast and within  
105 few months reached almost all countries around the globe (Worldometers, 2020). As of 02<sup>nd</sup>  
106 May 2021, there are more than 150 million confirmed cases of COVID-19 and approximately  
107 3 million deaths worldwide. This virus has caused global healthcare emergency because of  
108 its fast spread and sudden exponential rise in the COVID-19 patients and declared  
109 pandemic by world health organisation (WHO) (Cucinotta and Vanelli, 2020). This pandemic  
110 has caused enormous economic losses due to closure of most of the economic activities  
111 worldwide.

112 As the SARS-CoV-2 spread to other geographical areas with different climatic conditions  
113 compared to Wuhan, China, it started to mutate (Pachetti et al., 2020). The mutations  
114 acquired by the SARS-CoV-2 are retained as a consequence of natural selection, if the  
115 variants are more adaptable to the new conditions. In order to understand the variations  
116 occurring in RdRp among Indian geographical area, we analysed 668 RdRp sequences  
117 reported from India to identified sixty mutations. The B cell epitopes contributed by RdRp  
118 were predicted in silico, their functional consequences as well as the possible effect of  
119 mutations on them have been discussed.

120

## 121 MATERIAL AND METHODS

### 122 *Protein Sequences retrieval from NCBI-virus-database*

123 NCBI-virus-database is a repository for the nucleotide and protein sequences. This database  
124 also has protein sequences of SARS-CoV-2 that are available for users. We download the  
125 sequences of Orf1ab that contains all non-structural proteins including the RdRp sequence  
126 as described earlier (Azad, 2020). As of 10<sup>th</sup> April 2021, NCBI-virus-database has 668  
127 sequences deposited from the Indian COVID-19 patients. The supplementary table 1 shows  
128 the list of protein identifier accession number used in this analysis. The RdRp is located from  
129 4393 to 5324 residues in Orf1ab which corresponds to 932 amino acids in length. The RdRp  
130 reference or wild type sequence was also downloaded from NCBI virus database. The  
131 accession number of reference sequence used in this study is YP\_009724389 which is the  
132 first reported sequence of SARS-CoV-2 from Wuhan, China (Wu et al., 2020).

133

### 134 *Identification of RdRp mutants by multiple sequence alignments (MSAs)*

135 In order to identify the variations present in the RdRp sequences among Indian isolates of  
136 SARS-CoV-2, the MSAs were conducted by Clustal omega programe (Madeira et al., 2019)  
137 as described earlier (Azad, 2021a). First, we uploaded the RdRp sequences in Clustal  
138 omega webserver and run the programe that uses HMM and pairwise alignment to generate  
139 the data. The variations from the reference sequence were properly marked and used for  
140 further analysis.

141

### 142 *B cell epitope prediction*

143 B cell prediction methods to predict Linear B cell epitopes based on sequence  
144 characteristics of the antigen using amino acid scales and HMMs. The prediction of linear  
145 continuous B cell epitopes were conducted by IEDB (Immune Epitope Database and  
146 Analysis Resource) (Vita et al., 2019). The IEDB is an online server tool which predicts  
147 epitopes by a prediction method known as 'Bepipred linear epitope prediction method 2.0'.  
148 For this prediction the threshold value of 0.500 was used during the evaluation.

149 The prediction of discontinuous B cell epitopes was performed by an online tool 'DiscoTope  
150 2.0'. For this prediction the threshold value was set at -3.7.

151

### 152 *Protein modelling studies*

153 We performed protein modelling studies to understand the variation observed in the  
154 secondary structure might have any consequences on the three-dimensional structure of  
155 protein. This analysis was performed by DynaMut programme (Rodrigues et al., 2018) as  
156 described earlier (Azad, 2021b). This server uses the solved crystal structure of proteins and  
157 predicts the effect of mutation on the stability, intramolecular interaction and molecular  
158 fluctuations in the protein structure. For this study, we used recently reported structure of  
159 RdRp (PDB ID: 7BV1)(Yin et al., 2020). The effect of mutations on protein is shown in terms  
160 of difference in free energy ( $\Delta\Delta G$ ). The positive value indicates stabilizing mutation;  
161 however, negative value represents destabilizing mutation. DynaMut provides difference in  
162 vibrational entropy ( $\Delta\Delta S_{vib}$  ENCOM) between the wild type and mutant protein. The positive  
163  $\Delta\Delta S_{vib}$  ENCOM indicates increase in protein flexibility and negative  $\Delta\Delta S_{vib}$  ENCOM  
164 represents increase in rigidity of protein structure due to mutations. We ran DynaMut  
165 webserver to calculate the  $\Delta\Delta G$  and  $\Delta\Delta S_{vib}$  ENCOM that provides the impact of mutation on  
166 protein structure and stability. DynaMut server also provides the visual representation of the  
167 intramolecular interactions contributed by wild type and mutant residues with the  
168 neighbouring residues.

169

## 170 RESULTS

171

### 172 *RdRp is frequently mutated among Indian isolates of SARS-CoV-2*

173 In order to identify the mutations in RdRp, we compared the first reported sequence of RdRp  
174 from Wuhan, China with the sequences reported from India. In this analysis, we used 668  
175 RdRp sequences reported from India and performed Clustal Omega mediated multiple  
176 sequence alignment with an aim to identify variations in amino acids between the  
177 sequences. The RdRp polypeptide sequence reported from Wuhan, China was used as wild  
178 type sequence. Our data revealed sixty mutations present among the Indian sequences of  
179 RdRp as shown in table 1. The table also shows the location of each mutation in the RdRp  
180 polypeptide sequences and the effect of mutation on amino acid charge and polarity. The  
181 mutations are also demonstrated on the schematic representation of RdRp as shown in  
182 figure 1A and B. Our result show that the mutations are spreading all over the RdRp  
183 polypeptide sequence. The distribution of mutations in different domains of RdRp has been  
184 highlighted in figure 1B. Our MSA data strongly indicates that RdRp is one of the most

185 frequently mutated protein of SARS-CoV-2 because we observed sixty mutations in just 668  
186 sequences analysed in this study.

187

### 188 *Mutations affect RdRp protein dynamic stability and flexibility*

189 We performed protein modelling studies using DynaMut programme to understand, if the  
190 mutation observed in RdRp can alter protein structural integrity. The DynaMut programme  
191 does protein modelling for those proteins whose crystal structure has been solved. For this  
192 protein modelling study, we used recently reported crystal structure of RdRp (PDB ID:  
193 7BV1)(Yin et al., 2020). First, we calculated the differences in free energy ( $\Delta\Delta G$ ) between  
194 wild-type and mutant. Our data revealed that mutations at twenty-two positions cause  
195 stabilisation in protein structure (positive  $\Delta\Delta G$ ) as shown in table 2, maximum positive  $\Delta\Delta G$   
196 was obtained for D833Y (1.372 kcal/mol). Similarly, the mutations at twenty-eight positions  
197 cause destabilisation (negative  $\Delta\Delta G$ ) in protein structure upon mutation (Table 2), maximum  
198 negative  $\Delta\Delta G$  was obtained for the mutant A699S (-2.233 kcal/mol).

199 Next, we measured the changes in vibrational entropy energy ( $\Delta\Delta SVibENCoM$ ) between the  
200 wild type and the mutant. The negative and positive  $\Delta\Delta SVibENCoM$  values depict the  
201 rigidification and gain in protein flexibility upon mutation, respectively. Our data revealed that  
202 mutation at twenty-seven positions causes increase in flexibility of mutant protein (positive  
203  $\Delta\Delta SVibENCoM$ ). The maximum positive  $\Delta\Delta SVibENCoM$  was obtained for Y149C (1.065  
204 kcal.mol<sup>-1</sup>.K<sup>-1</sup>) mutant. Similarly, the mutations at rest of the twenty-three positions cause  
205 rigidification of protein structure (negative  $\Delta\Delta SVibENCoM$ ) in protein structure upon mutation  
206 (Table 2). The maximum negative  $\Delta\Delta SVibENCoM$  was obtained for C464F (-1.092 kcal.mol<sup>-1</sup>.  
207 K<sup>-1</sup>) mutant. Altogether, our data revealed that the mutation observed in RdRp affects both  
208 protein dynamicity and flexibility.

209

### 210 *Identification of B cell epitopes of RdRp*

211 The continuous B-cell epitopes of RdRp were predicted by IEDB webserver tool and the  
212 epitopes are shown in figure 2A. The yellow area of the graph corresponds to those regions  
213 of the RdRp that can potentially contribute to the B cell epitopes. Our data demonstrated  
214 thirty-six epitopes of varying lengths that could potentially act as B cell epitopes (figure 2B).  
215 Among those peptides, the 'peptide 18' is the largest epitopes, which is forty-four amino acid  
216 in length (from RdRp residue 482 to 525). Similarly, peptide 5, 19, 30, 31 and 34 are  
217 comprised of single amino acid only (figure 2B).

218 Subsequently, we predicted the B cell epitopes of RdRp based on its three dimensional  
219 structure using DiscoTope 2.0 webserver tool (Kringelum et al., 2012). Our analysis  
220 revealed twenty-five discontinuous epitopes of RdRp having high score. The locations of  
221 these epitopes are highlighted in figure 2C along with its propensity and DiscoTope score.

222 Among discontinuous epitopes, approximately 80% of them (20 out of 25) reside towards the  
223 C-terminal end of RdRp (from residue 800 to 932) as shown in figure 2C. Altogether, our  
224 data revealed B cell epitopes contributed by RdRp.

225

226 *RdRp mutants preferentially localises in the B cell epitopes region*

227 Subsequently, we analysed and compared the RdRp mutations that reside in the linear-  
228 continuous and discontinuous B cell epitopes. Our data revealed that out of 60 mutants  
229 observed in this study, 24 resides in the B cell epitope region of RdRp (figure 3A). These 24  
230 mutants correspond to 40% of the total mutants observed among Indian isolates. The details  
231 of all 24 mutants that localises in B cell epitope region are shown in figure 3B. Altogether,  
232 our data strongly suggest that RdRp mutants preferentially localises in B cell epitope region.

233

234

## 235 DISCUSSION

236 The coronaviruses belongs to RNA viruses that exhibits high rate of mutations in their  
237 genome (Benvenuto et al., 2020). As these viruses spread to new locations they keep on  
238 acquiring mutations and few of them are naturally selected because of their beneficial effect  
239 on the virus. The SARS-CoV-2 was first reported from Wuhan, china and within a span of  
240 few months it spread to almost all countries worldwide (Worldometers, 2020). The  
241 researchers around the globe sequenced the SARS-CoV-2 to understand the genomic  
242 properties of this virus and soon identify various mutations. The investigation on the genomic  
243 variation acquired by SARS-CoV-2 is indispensable for understanding the epidemiology,  
244 pathogenesis; devise preventive measures and treatment strategies against COVID-19.

245 The earlier variation studies on SARS-CoV-2 revealed that RdRp is among the mutational  
246 hotspot protein (Pachetti et al., 2020). In the similar directions, this study was conducted with  
247 an aim to identify mutations in RdRp from Indian isolates. Our earlier study revealed seven  
248 crucial mutations in RdRp of SARS-CoV-2 (Chand et al., 2020) that can have potential  
249 impact on this protein function. The present study identifies and characterises B cell epitope  
250 contributed by RdRp and correlate them with the observed mutants. In this study, we  
251 analysed 668 RdRp sequences reported from India till April 2021 date and identified sixty  
252 mutations in RdRp. Our protein modelling studies revealed various interesting mutations  
253 including D833Y, A699S, Y149C and C464F (table 2) that can potentially affect stability and  
254 flexibility of RdRp. So far, we analysed 668 sequences from India and identified sixty  
255 mutations which indicates that RdRp is one of the mutational hotspot protein of SARS-CoV-2  
256 in India. Furthermore, we did prediction study to identify B cell epitopes contributed by RdRp.  
257 Our data revealed that there are thirty-six high rank linear- continuous B cell epitope as well  
258 as twenty-five discontinuous B cell epitopes. Moreover, we also identified that out of sixty

259 mutants identified among Indian isolates, twenty-four resides (40%) in these B cell epitope  
260 region.

261 The variations in RdRp or any other protein of SARS-CoV-2 will possibly tell us how the virus  
262 is evolving. Earlier studies with RNA viruses have also shown that these viruses keep on  
263 mutating to better adapt and survive in the host (Sanjuán and Domingo-Calap, 2016). Here,  
264 in this study, we have reported RdRp mutations, its correlation with B cell epitopes.  
265 However, it warrants future studies to understand the possible effect of these mutations on  
266 virus infectivity and life cycle.

267

## 268 CONCLUSIONS

269 The pandemic caused by SARS-CoV-2 have adverse impact on health services worldwide  
270 with economic fallout of most of the countries. Understanding the genetic variations in  
271 SARS-CoV-2 will help to better devise the preventive and treatment strategies against this  
272 virus. Here, our data show various mutations in RdRp from India and their impact on B cell  
273 epitopes by *in silico* studies. Altogether, the data presented here could help scientific  
274 community to better understand the immunological aspect of SARS-CoV-2.

275

## 276 ACKNOWLEDGEMENTS

277 We would like to acknowledge Patna University, Patna, Bihar (India) for providing  
278 infrastructural support for this study.

279

## 280 REFERENCES

- 281 Azad, G.K., 2021a. The molecular assessment of SARS-CoV-2 Nucleocapsid  
282 Phosphoprotein variants among Indian isolates. Heliyon.  
283 <https://doi.org/10.1016/j.heliyon.2021.e06167>
- 284 Azad, G.K., 2021b. Identification and molecular characterization of mutations in  
285 nucleocapsid phosphoprotein of SARS-CoV-2. PeerJ.  
286 <https://doi.org/10.7717/peerj.10666>
- 287 Azad, G.K., 2020. Identification of novel mutations in the methyltransferase complex (Nsp10-  
288 Nsp16) of SARS-CoV-2. Biochem. Biophys. Reports.  
289 <https://doi.org/10.1016/j.bbrep.2020.100833>
- 290 Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., Ciccozzi, M., 2020. The  
291 2019-new coronavirus epidemic: Evidence for virus evolution. J. Med. Virol.  
292 <https://doi.org/10.1002/jmv.25688>
- 293 Chan, J.F.W., Kok, K.H., Zhu, Z., Chu, H., To, K.K.W., Yuan, S., Yuen, K.Y., 2020. Genomic  
294 characterization of the 2019 novel human-pathogenic coronavirus isolated from a  
295 patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect.



- 296 <https://doi.org/10.1080/22221751.2020.1719902>
- 297 Chand, G.B., Banerjee, A., Azad, G.K., 2020. Identification of novel mutations in RNA-  
298 dependent RNA polymerases of SARS-CoV-2 and their implications on its protein  
299 structure. *PeerJ* 8, e9492. <https://doi.org/10.7717/peerj.9492>
- 300 Cucinotta, D., Vanelli, M., 2020. WHO declares COVID-19 a pandemic. *Acta Biomed.*  
301 <https://doi.org/10.23750/abm.v91i1.9397>
- 302 Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang,  
303 L., Ge, J., Zheng, L., Zhang, Y., Wang, H., Zhu, Y., Zhu, C., Hu, T., Hua, T., Zhang, B.,  
304 Yang, X., Li, J., Yang, H., Liu, Z., Xu, W., Guddat, L.W., Wang, Q., Lou, Z., Rao, Z.,  
305 2020. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science*  
306 (80- ). <https://doi.org/10.1126/science.abb7498>
- 307 Gorbalenya, A.E., Baker, S.C., Baric, R.S., de Groot, R.J., Drosten, C., Gulyaeva, A.A.,  
308 Haagmans, B.L., Lauber, C., Leontovich, A.M., Neuman, B.W., Penzar, D., Perlman, S.,  
309 Poon, L.L.M., Samborskiy, D. V., Sidorov, I.A., Sola, I., Ziebuhr, J., 2020. The species  
310 Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and  
311 naming it SARS-CoV-2. *Nat. Microbiol.* <https://doi.org/10.1038/s41564-020-0695-z>
- 312 Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., O'Meara, M.J.,  
313 Rezelj, V. V., Guo, J.Z., Swaney, D.L., Tummino, T.A., Huettenhain, R., Kaake, R.M.,  
314 Richards, A.L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., Kim, M.,  
315 Haas, P., Polacco, B.J., Braberg, H., Fabius, J.M., Eckhardt, M., Soucheray, M.,  
316 Bennett, M.J., Cakir, M., McGregor, M.J., Li, Q., Meyer, B., Roesch, F., Vallet, T., Mac  
317 Kain, A., Miorin, L., Moreno, E., Naing, Z.Z.C., Zhou, Y., Peng, S., Shi, Y., Zhang, Z.,  
318 Shen, W., Kirby, I.T., Melnyk, J.E., Chorba, J.S., Lou, K., Dai, S.A., Barrio-Hernandez,  
319 I., Memon, D., Hernandez-Armenta, C., Lyu, J., Mathy, C.J.P., Perica, T., Pilla, K.B.,  
320 Ganesan, S.J., Saltzberg, D.J., Rakesh, R., Liu, X., Rosenthal, S.B., Calviello, L.,  
321 Venkataramanan, S., Liboy-Lugo, J., Lin, Y., Huang, X.P., Liu, Y.F., Wankowicz, S.A.,  
322 Bohn, M., Safari, M., Ugur, F.S., Koh, C., Savar, N.S., Tran, Q.D., Shengjuler, D.,  
323 Fletcher, S.J., O'Neal, M.C., Cai, Y., Chang, J.C.J., Broadhurst, D.J., Klippsten, S.,  
324 Sharp, P.P., Wenzell, N.A., Kuzuoglu, D., Wang, H.Y., Trenker, R., Young, J.M.,  
325 Cavero, D.A., Hiatt, J., Roth, T.L., Rathore, U., Subramanian, A., Noack, J., Hubert, M.,  
326 Stroud, R.M., Frankel, A.D., Rosenberg, O.S., Verba, K.A., Agard, D.A., Ott, M.,  
327 Emerman, M., Jura, N., von Zastrow, M., Verdin, E., Ashworth, A., Schwartz, O.,  
328 d'Enfert, C., Mukherjee, S., Jacobson, M., Malik, H.S., Fujimori, D.G., Ideker, T., Craik,  
329 C.S., Floor, S.N., Fraser, J.S., Gross, J.D., Sali, A., Roth, B.L., Ruggero, D., Taunton,  
330 J., Kortemme, T., Beltrao, P., Vignuzzi, M., García-Sastre, A., Shokat, K.M., Shoichet,  
331 B.K., Krogan, N.J., 2020. A SARS-CoV-2 protein interaction map reveals targets for  
332 drug repurposing. *Nature*. <https://doi.org/10.1038/s41586-020-2286-9>

- 333 Kringelum, J.V., Lundegaard, C., Lund, O., Nielsen, M., 2012. Reliable B Cell Epitope  
334 Predictions: Impacts of Method Development and Improved Benchmarking. *PLoS*  
335 *Comput. Biol.* <https://doi.org/10.1371/journal.pcbi.1002829>
- 336 Madeira, F., Park, Y.M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey,  
337 A.R.N., Potter, S.C., Finn, R.D., Lopez, R., 2019. The EMBL-EBI search and sequence  
338 analysis tools APIs in 2019. *Nucleic Acids Res.* <https://doi.org/10.1093/nar/gkz268>
- 339 Mcdonald, S.M., 2013. RNA synthetic mechanisms employed by diverse families of RNA  
340 viruses. *Wiley Interdiscip. Rev. RNA.* <https://doi.org/10.1002/wrna.1164>
- 341 Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storicci, P., Masciovecchio, C.,  
342 Angeletti, S., Ciccozzi, M., Gallo, R.C., Zella, D., Ippodrino, R., 2020. Emerging SARS-  
343 CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *J.*  
344 *Transl. Med.* <https://doi.org/10.1186/s12967-020-02344-6>
- 345 Peng, Q., Peng, R., Yuan, B., Zhao, J., Wang, M., Wang, X., Wang, Q., Sun, Y., Fan, Z., Qi,  
346 J., Gao, G.F., Shi, Y., 2020. Structural and biochemical characterization of nsp12-nsp7-  
347 nsp8 core polymerase complex from SARS-CoV-2. *Cell Rep.*  
348 <https://doi.org/10.1016/j.celrep.2020.107774>
- 349 Rodrigues, C.H.M., Pires, D.E.V., Ascher, D.B., 2018. DynaMut: Predicting the impact of  
350 mutations on protein conformation, flexibility and stability. *Nucleic Acids Res.*  
351 <https://doi.org/10.1093/nar/gky300>
- 352 Sanjuán, R., Domingo-Calap, P., 2016. Mechanisms of viral mutation. *Cell. Mol. Life Sci.*  
353 <https://doi.org/10.1007/s00018-016-2299-6>
- 354 Te Velthuis, A.J.W., Van Den Worm, S.H.E., Snijder, E.J., 2012. The SARS-coronavirus  
355 nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo  
356 initiation and primer extension. *Nucleic Acids Res.* <https://doi.org/10.1093/nar/gkr893>
- 357 Vita, R., Mahajan, S., Overton, J.A., Dhanda, S.K., Martini, S., Cantrell, J.R., Wheeler, D.K.,  
358 Sette, A., Peters, B., 2019. The Immune Epitope Database (IEDB): 2018 update.  
359 *Nucleic Acids Res.* <https://doi.org/10.1093/nar/gky1006>
- 360 World Health Organization, 2020. Naming the coronavirus disease (COVID-19) and the virus  
361 that causes it. *World Heal. Organ.*
- 362 Worldometers, 2020. COVID-19 CORONAVIRUS PANDEMIC [WWW Document].  
363 Worldometers. <https://doi.org/>
- 364 Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H.,  
365 Pei, Y.Y., Yuan, M.L., Zhang, Y.L., Dai, F.H., Liu, Y., Wang, Q.M., Zheng, J.J., Xu, L.,  
366 Holmes, E.C., Zhang, Y.Z., 2020. A new coronavirus associated with human respiratory  
367 disease in China. *Nature.* <https://doi.org/10.1038/s41586-020-2008-3>
- 368 Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W.,  
369 Gao, M., Chang, S., Xie, Y.-C., Tian, G., Jiang, H.-W., Tao, S.-C., Shen, J., Jiang, Y.,

370 Jiang, H., Xu, Y., Zhang, S., Zhang, Y., Xu, H.E., 2020. Structural basis for inhibition of  
371 the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science* (80-. ).  
372 <https://doi.org/10.1126/science.abc1560>  
373 Zhai, Y., Sun, F., Li, X., Pang, H., Xu, X., Bartlam, M., Rao, Z., 2005. Insights into SARS-  
374 CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer.  
375 *Nat. Struct. Mol. Biol.* <https://doi.org/10.1038/nsmb999>  
376

## 377 TABLE AND FIGURE LEGENDS

378

379 Table 1. The list demonstrates the location and details of mutations of RdRp identified by  
380 Clustal Omega multiple sequence alignments. The RdRp sequence reported from Wuhan,  
381 China was used as wild type sequence for this analysis. The 668 sequences of RdRp  
382 reported from India were used for identifying mutations.

383

<b>S. No.</b>	<b>Wild-type</b>	<b>Charge Changes</b>	<b>Polarity Changes</b>
1	K59N	Basic to Neutral	P to P
2	T85I	Neutral to Neutral	P to NP
3	K91N	Basic to Neutral	P to P
4	P94S	Neutral to Neutral	NP to P
5	A95V	Neutral to Neutral	NP to P
6	A97V	Neutral to Neutral	NP to P
7	I101L	Neutral to Neutral	NP to NP
8	M110K	Neutral to Basic	NP to P
9	R118C	Basic to Neutral	P to P
10	Y122F	Neutral to Neutral	P to NP
11	D140G	Acidic to Neutral	P to NP
12	T141I	Neutral to Neutral	P to NP
13	E144K	Acidic to Basic	P to P
14	T148I	Neutral to Neutral	P to NP
15	Y149C	Neutral to Neutral	P to P
16	R173H	Basic to Basic	P to P
17	A185V	Neutral to Neutral	NP to NP
18	M196I	Neutral to Neutral	NP to NP
19	I201L	Neutral to Neutral	NP to NP
20	T248I	Neutral to Neutral	P to NP
21	D269N	Acidic to Neutral	P to P
22	E278D	Acidic to Acidic	P to P
23	D284Y	Acidic to Neutral	P to P
24	T293I	Neutral to Neutral	P to NP
25	H295Y	Basic to Neutral	P to P
26	P323L	Neutral to Neutral	NP to NP

27	L329I	Neutral to Neutral	NP to NP
28	V342A	Neutral to Neutral	P to NP
29	V342L	Neutral to Neutral	NP to NP
30	V354A	Neutral to Neutral	P to NP
31	V354L	Neutral to Neutral	NP to NP
32	V398L	Neutral to Neutral	NP to NP
33	A406V	Neutral to Neutral	NP to NP
34	M463I	Neutral to Neutral	NP to NP
35	C464F	Acidic to Neutral	P to NP
36	I488S	Neutral to Neutral	NP to P
37	A526V	Neutral to Neutral	NP to NP
38	I536T	Neutral to Neutral	NP to P
39	V605A	Neutral to Neutral	NP to NP
40	M608I	Neutral to Neutral	NP to NP
41	L638F	Neutral to Neutral	NP to NP
42	T643I	Neutral to Neutral	P to NP
43	T644M	Neutral to Neutral	P to NP
44	S647I	Neutral to Neutral	P to NP
45	M668I	Neutral to Neutral	NP to NP
46	A699S	Neutral to Neutral	NP to P
47	L775P	Neutral to Neutral	NP to NP
48	E802A	Acidic to Neutral	P to NP
49	S814P	Neutral to Neutral	P to NP
50	Q822H	Neutral to Basic	P to P
51	D833Y	Acidic to Neutral	P to P
52	T848I	Neutral to Neutral	P to NP
53	S853L	Neutral to Neutral	P to NP
54	V880I	Neutral to Neutral	NP to NP
55	D893Y	Acidic to Neutral	P to P
56	Y908I	Neutral to Neutral	P to NP
57	T909I	Neutral to Neutral	P to NP
58	S913L	Neutral to Neutral	P to NP
59	S919L	Neutral to Neutral	P to NP
60	P925S	Neutral to Neutral	NP to P

384

385 Table 2. The  $\Delta\Delta G$  and  $\Delta\Delta S_{vib}$  ENCOM values obtained by protein modelling using DynaMut  
 386 programme. The positive and negative  $\Delta\Delta G$  represents increase and decrease in protein  
 387 stability upon mutation. Similarly, the positive and negative  $\Delta\Delta S_{vib}$  ENCOM represents the  
 388 increase in flexibility and rigidity upon mutations.

389

S. No.	Mutation	$\Delta\Delta G$ (kcal/mol)	$\Delta\Delta S_{vib}$ ENCOM (kcal.mol <sup>-1</sup> .K <sup>-1</sup> )
1	T85I	-0.707	-0.074
2	K91N	-0.311	0.295

3	P94S	-0.035	-0.131
4	A95V	-0.669	-0.627
5	A97V	0.469	-1.020
6	R118C	0.005	0.055
7	Y122F	0.225	0.273
8	D140G	-0.18	0.035
9	T141I	1.041	-0.231
10	E144K	-0.236	0.353
11	T148I	1.156	-0.098
12	Y149C	0.237	1.065
13	R173H	-0.284	0.01
14	A185V	-0.179	-0.369
15	M196I	-0.554	0.094
16	I201L	0.105	0.057
17	T248I	0.452	-0.08
18	D269N	-0.362	0.08
19	E278D	-0.714	0.103
20	D284Y	0.346	-0.459
21	T293I	0.264	-0.016
22	H295Y	0.304	0.141
23	P323L	0.53	-0.252
24	L329I	0.081	0.231
25	V342A	-0.454	0.402
26	V342L	1.027	-0.025
27	V354A	-1.811	0.277
28	V354L	-0.162	-0.387
29	V398L	0.37	0.031
30	A406V	-0.148	-0.047
31	M463I	0.483	0.25
32	C464F	1.251	-1.092
33	I488S	-1.617	0.205
34	A526V	0.305	-0.109
35	I536T	-1.703	0.348
36	V605A	-1.528	0.596
37	L638F	-0.167	-0.297
38	T643I	-0.383	-0.074
39	T644M	-0.084	-0.037
40	S647I	-0.272	0.166
41	M668I	0.104	0.066
42	A699S	-2.233	-0.185
43	L775P	-0.6	0.754
44	E802A	-0.835	0.49
45	S814P	-0.083	0.113
46	Q822H	0.006	0.514

47	D833Y	1.372	-0.397
48	V880I	-0.087	-0.146
49	D893Y	0.088	-0.168
50	S913L	-0.116	0.012

390

391 Figure 1: The details of the mutation identified in RdRp among Indian SARS-CoV-2 isolates.

392 A) Schematic diagram of the domain architecture of RdRp. Each domain of RdRp is  
393 represented by a unique color. The interdomain borders are labeled with residue numbers.

394 B) The mutations present in RdRp among the Indian isolates of SARS-CoV-2 are  
395 demonstrated in the schematics.

396

397 Figure 2: Prediction of B-cell epitopes of RdRp. A) Linear continuous B-cell epitopes

398 contributed by RdRp, the Y-axis of the graph corresponds to BepiPred score, while the X-

399 axis depicts the RdRp residue positions in the sequence. The data was generated by IEDB

400 webserver using 'Bepipred Linear Epitope Prediction 2.0' method. The chart is divided into

401 two parts yellow and green. The RdRp residues present in the yellow have higher probability

402 to be part of the linear continuous B cell epitope. B) The details of the linear continuous B

403 cell epitopes are listed. The sequence of each peptide along with its start and end point in

404 the RdRp polypeptide sequence is also mentioned. C) Prediction of discontinuous B-cell

405 epitopes of RdRp by DiscoTope 2.0 web tool. The position of each predicted epitope is

406 mentioned along with its propensity and DiscoTope score.

407

408 Figure 3: Correlation of RdRp mutants and B cell epitopes. A) the graph shows the

409 distribution of RdRp mutants observed among Indian SARS-CoV-2 isolates. Out of 60, 24

410 mutants localises in B cell epitope region of RdRp. B) Detail of the RdRp mutants that

411 localises in B cell epitope region.

412

413 Supplementary Table 1: List of protein identifier accession number used in this analysis. The

414 sequences of each protein can be downloaded from NCBI-Virus-Database using the

415 accession number provided in the list.

YP_009724389	QOS50986.1	QNL90834.1	QLI49743.1	QKY60095.1	QKJ84977.1	QJX44644.1
QTV76173.1	QOS51010.1	QNL90846.1	QLI49755.1	QKY60107.1	QKG91164.1	QJX44656.1
QTP17383.1	QOS51022.1	QNL90858.1	QLI49767.1	QKY60119.1	QKG91176.1	QJX44668.1
QTH36343.1	QOS51058.1	QNL90870.1	QLI49779.1	QKY60131.1	QKG91188.1	QJX44680.1
QTH36355.1	QOS51070.1	QNL90882.1	QLI49791.1	QKY60163.1	QKG91200.1	QJW39842.1
QTH36367.1	QOS51082.1	QNL90894.1	QLI49803.1	QKY60175.1	QKG91212.1	QJW39854.1
QTH36379.1	QOS51094.1	QNL90906.1	QLI49815.1	QKY60187.1	QKG91224.1	QJW39866.1
QTH36391.1	QOS51106.1	QNL90918.1	QLI52055.1	QKY60199.1	QKG91236.1	QJW39878.1
QTH36403.1	QOS51118.1	QNL98443.1	QLI52067.1	QKY60211.1	QKG91248.1	QJW39890.1

QTH36415.1	QOR63432.1	QNL98455.1	QLH64777.1	QKY60223.1	QKG91260.1	QJW39902.1
QTH36427.1	QOR63444.1	QNL98467.1	QLH64789.1	QKY60235.1	QKG91272.1	QJW39914.1
QTH36439.1	QOR63456.1	QNL98479.1	QLH64801.1	QKY60262.1	QKG91284.1	QJW39926.1
QTH36451.1	QOR63468.1	QNL35816.1	QLH64813.1	QKY64328.1	QKH78808.1	QJW69137.1
QTH36723.1	QOR63480.1	QNL35828.1	QLH64825.1	QKY64344.1	QKH78820.1	QJU70555.1
QTG68689.1	QOR63504.1	QNL35840.1	QLH64837.1	QKY64358.1	QKI10470.1	QJT43414.1
QTG68602.1	QOR64231.1	QNL35852.1	QLH64849.1	QKY64612.1	QKI28575.1	QJT43426.1
QTG68615.1	QOR64243.1	QNL35864.1	QLH64861.1	QKY64638.1	QKI28587.1	QJT43438.1
QTG40603.1	QOQ57010.1	QNL35876.1	QLH64875.1	QKY64790.1	QKI28599.1	QJT43450.1
QRY06669.1	QOQ57022.1	QNL35888.1	QLH64887.1	QKY65275.1	QKI28611.1	QJT43462.1
QRQ47003.1	QOQ57034.1	QNL35900.1	QLH64899.1	QKV25883.1	QKI28623.1	QJT43474.1
QRQ47018.1	QOQ57046.1	QNL35912.1	QLH64915.1	QKV25895.1	QKI28635.1	QJT43486.1
QRQ47032.1	QOQ57058.1	QNL35924.1	QLH64927.1	QKV25907.1	QKI28647.1	QJT43498.1
QRQ47071.1	QOQ57070.1	QNL35936.1	QLH64939.1	QKV25919.1	QKI28659.1	QJT43510.1
QRQ47083.1	QOQ57082.1	QNL35948.1	QLH90040.1	QKV25931.1	QKI28671.1	QJT43522.1
QRQ69195.1	QOQ57094.1	QNL35960.1	QLH90076.1	QKV25943.1	QKI28683.1	QJT43534.1
QRQ69279.1	QOQ57106.1	QNL35972.1	QLH90088.1	QKV25955.1	QKE61658.1	QJT43546.1
QRN68229.1	QOQ57119.1	QNL35984.1	QLH90101.1	QKV25967.1	QKE61670.1	QJT43558.1
QRN68241.1	QOQ72542.1	QNL35996.1	QLH93117.1	QKV25979.1	QKE61682.1	QJT43570.1
QRN68253.1	QOQ72554.1	QNL36008.1	QLH93129.1	QKV25991.1	QKE61694.1	QJT43582.1
QRN68266.1	QOQ72566.1	QNL36560.1	QLH93185.1	QKV26003.1	QKE61706.1	QJT43594.1
QRN68278.1	QOQ72578.1	QLY82444.1	QLH93199.1	QKV26015.1	QKE61718.1	QJT43606.1
QRN68302.1	QOQ84793.1	QLY82482.1	QLH93212.1	QKV26027.1	QKE61730.1	QJT43618.1
QRN68400.1	QOQ84824.1	QLY82500.1	QLH93283.1	QKV26039.1	QKE61742.1	QJT43630.1
QRN68424.1	QKM77202.1	QLY82512.1	QLF97937.1	QKV26051.1	QKE61754.1	QJT43642.1
QRN68442.1	QKM77214.1	QMC85346.1	QLF97949.1	QKV26063.1	QKE61766.1	QJT43654.1
QRM36235.1	QKM77226.1	QLQ87394.1	QLF97985.1	QKV26075.1	QKE61778.1	QJT43666.1
QRM91443.1	QKM77238.1	QLQ87406.1	QLF97997.1	QKV26087.1	QKE61790.1	QJT43678.1
QRE02629.2	QKM77250.1	QLQ87418.1	QLF98069.1	QKV27549.1	QKE61802.1	QJT43690.1
QRC50281.1	QKM77262.1	QLQ87430.1	QLF98081.1	QKV27561.1	QJY77053.1	QJT43702.1
QRC50293.1	QKM77274.1	QLQ87442.1	QLF98093.1	QKV27573.1	QJY51262.1	QJT43714.1
QRC50305.1	QNO30921.1	QLQ87454.1	QLF98105.1	QKV27585.1	QJY51274.1	QJT43726.1
QRC50340.1	QNO30933.1	QLQ87466.1	QLF98117.1	QKQ29884.1	QJY51286.1	QJS39637.1
QRC50364.1	QNN87972.1	QLQ87478.1	QLF98129.1	QKQ29944.1	QJY51346.1	QJS39649.1
QRC50492.1	QNN87984.1	QLQ87490.1	QLF98141.1	QKQ29956.1	QJY51358.1	QJR84343.1
QQJ94103.1	QNN87996.1	QLQ87502.1	QLF98153.1	QKQ29968.1	QJY51370.1	QJR84367.1
QQJ95306.1	QNN88008.1	QLQ87514.1	QLF98165.1	QKQ30028.1	QJY51382.1	QJR84379.1
QQH18637.1	QNN88020.1	QLQ87526.1	QLF98178.1	QKQ30040.1	QJY40383.1	QJR84391.1
QPZ33508.1	QNN88068.1	QLQ87550.1	QLF98198.1	QKQ30052.1	QJY40395.1	QJR84415.1
QPB40017.1	QNN88080.1	QLQ87574.1	QLF98210.1	QKQ30064.1	QJY40407.1	QJR84427.1
QPB40029.1	QNN88092.1	QLQ87598.1	QLF98222.1	QKQ30076.1	QJY40419.1	QJR84439.1
QPB40041.1	QNN88104.1	QLQ87610.1	QLF98234.1	QKQ30088.1	QJY40431.1	QJR84451.1
QPB40053.1	QNN88116.1	QLQ87622.1	QLF98246.1	QKQ30100.1	QJY40443.1	QJR84463.1
QPB40065.1	QNN88128.1	QLQ87634.1	QLF98258.1	QKQ30112.1	QJY40455.1	QJR84475.1
QPB40077.1	QNN88140.1	QLQ87658.1	QLF98275.1	QKQ30124.1	QJY40467.1	QJR84487.1
QPB40089.1	QNN88152.1	QLQ87682.1	QLF98287.1	QKQ30136.1	QJY40479.1	QJR84499.1


QPB40101.1	QNN88164.1	QLQ87694.1	QLA09686.1	QKQ30148.1	QJY40491.1	QJR84511.1
QPB40113.1	QNN88176.1	QLQ87706.1	QLA09698.1	QKQ30160.1	QJY40503.1	QJR84523.1
QPB40563.1	QNN88188.1	QLQ87718.1	QLA09710.1	QKQ30172.1	QJY40515.1	QJR84535.1
QPB40575.1	QNN88200.1	QLQ87730.1	QLA09722.1	QKQ30184.1	QJY40527.1	QJQ28343.1
QPB17918.1	QNN88212.1	QLQ87795.1	QLA09734.1	QKQ30196.1	QJY40539.1	QJQ28355.1
QPB17990.1	QNN88224.1	QLQ87983.1	QLA09746.1	QKQ30208.1	QJY40551.1	QJQ28367.1
QPB18014.1	QNN88236.1	QLQ87995.1	QLA09758.1	QKQ30220.1	QJY40563.1	QJQ28379.1
QPB18026.1	QNN88248.1	QLQ88046.1	QLA09770.1	QKQ30232.1	QJY40575.1	QJQ28391.1
QPB18050.1	QNN88260.1	QLQ88063.1	QLA09782.1	QKQ30244.1	QJY40587.1	QJQ28403.1
QPB18062.1	QNN88272.1	QLQ88075.1	QLA09794.1	QKQ30256.1	QJY40599.1	QJQ28415.1
QPB18074.1	QNN88284.1	QLQ88087.1	QLA09808.1	QKQ30268.1	QJW00289.1	QJQ28427.1
QPB18086.1	QNN88296.1	QLQ88102.1	QLA09820.1	QKQ63386.1	QJW00301.1	QJH92165.1
QPB18098.1	QNN88551.1	QLR06736.1	QLA09832.1	QKO00484.1	QJW00313.1	QJH92177.1
QPB18110.1	QNN88563.1	QLR06757.1	QLA09844.1	QKJ68410.1	QJW00325.1	QJF77844.1
QPB18122.1	QNN88575.1	QLR06769.1	QLA09856.1	QKJ68422.1	QJW00337.1	QJF77856.1
QPB18134.1	QNN88630.1	QLR06870.1	QLA09880.1	QKJ68434.1	QJW00349.1	QJF77868.1
QPB18158.1	QNN88642.1	QLR06882.1	QLA09904.1	QKJ68446.1	QJW00361.1	QJF77880.1
QPB18194.1	QNN88654.1	QLR06894.1	QLA10066.1	QKJ68458.1	QJW00373.1	QJC19489.1
QPB18206.1	QNN90122.1	QLR07146.1	QLA10078.1	QKJ68471.1	QJW00385.1	QHS34545.1
QPB39980.1	QNN90135.1	QLR07158.1	QLA10090.1	QKJ68483.1	QJW00397.1	QIA98582.1
QPB39992.1	QNN93013.1	QLR07170.1	QLA10102.1	QKJ68495.1	QJW00409.1	
QPB40004.1	QNN26334.1	QLR07182.1	QLA10114.1	QKJ68507.1	QJW00421.1	
QPA18453.1	QNN26346.1	QLR07194.1	QLA10126.1	QKJ68519.1	QJW00433.1	
QPA18457.1	QNN26358.1	QLR07206.1	QLA10138.1	QKJ68531.1	QJW00445.1	
QOW08181.2	QNN26370.1	QLR12235.1	QLA10150.1	QKJ68543.1	QJW00457.1	
QOU99168.1	QNN26382.1	QLR12247.1	QLA10162.1	QKJ68555.1	QJX44380.1	
QOU99261.1	QNN26394.1	QLR12259.1	QLA10174.1	QKJ68567.1	QJX44392.1	
QOU99272.1	QNN26406.1	QLR12271.1	QLA10186.1	QKJ68579.1	QJX44404.1	
QOU99283.1	QNN26418.1	QLR12283.1	QLA10198.1	QKJ68591.1	QJX44416.1	
QOU99294.1	QNN26430.1	QLR12295.1	QLA10210.1	QKJ68603.1	QJX44428.1	
QOS50509.1	QNN26442.1	QLR12307.1	QLA10222.1	QKJ68615.1	QJX44440.1	
QOS50580.1	QNN26454.1	QLR12319.1	QKY74626.1	QKJ68627.1	QJX44464.1	
QOS50592.1	QNN26466.1	QLR12331.1	QKY74638.1	QKJ68639.1	QJX44476.1	
QOS50604.1	QNN26478.1	QLR12343.1	QKY59939.1	QKJ68651.1	QJX44500.1	
QOS50616.1	QNN30834.1	QLR12355.1	QKY59951.1	QKJ68663.1	QJX44512.1	
QOS50628.1	QNN30858.1	QLR12415.1	QKY59963.1	QKJ68675.1	QJX44536.1	
QOS50676.1	QNN30870.1	QLR12438.1	QKY59975.1	QKJ68687.1	QJX44548.1	
QOS50712.1	QNN31194.1	QLR60574.1	QKY59987.1	QKJ68699.1	QJX44560.1	
QOS50879.1	QNN31206.1	QLR80398.1	QKY59999.1	QKJ68711.1	QJX44572.1	
QOS50891.1	QNN81330.1	QLS04049.1	QKY60023.1	QKJ68723.1	QJX44584.1	
QOS50926.1	QNN81490.1	QLI49695.1	QKY60047.1	QKJ68735.1	QJX44596.1	
QOS50938.1	QNN81502.1	QLI49707.1	QKY60059.1	QKJ84941.1	QJX44608.1	
QOS50950.1	QNN83660.1	QLI49719.1	QKY60071.1	QKJ84953.1	QJX44620.1	
QOS50962.1	QNN83672.1	QLI49731.1	QKY60083.1	QKJ84965.1	QJX44632.1	




417

418

Figure 1



**Figure 2**



**B**

**Linear- continuous B cell epitopes RdRp**

Epitopes	Peptide Start	Peptide End	Peptide Sequence
Peptide 1	8	28	LNRVCGVSAARLTPCGTGTST
Peptide 2	39	44	NDKVAG
Peptide 3	58	64	EKDEDDN
Peptide 4	76	88	TFSNYQHEETIYN
Peptide 5	91	91	K
Peptide 6	95	96	AV
Peptide 7	106	113	IDGDMVPH
Peptide 8	136	139	EGNC
Peptide 9	154	169	DDYFNKKDWYDFVENP
Peptide 10	211	231	DLNGNWFYDFGDFIQTTGSGV
Peptide 11	257	283	VDTDLTKPYIKWDLKDYDFTEERLKL
Peptide 12	288	303	KYWDQTYHPNCVNC
Peptide 13	318	326	STVFPPTSF
Peptide 14	360	366	NLHSSRL
Peptide 15	386	390	NLLLD
Peptide 16	405	436	VAFQTVKPGNFKDFYDFAVSKGFFKEGSSVE
Peptide 17	444	463	QDGNAAISDYDYRYNLPTM
Peptide 18	482	525	CYDGGCINANQVIVNNLDKSAGFPFNKWKGA RLYYDSMSYEDQD
Peptide 19	533	533	R
Peptide 20	536	537	IP
Peptide 21	547	552	AISAKN
Peptide 22	596	597	GG
Peptide 23	599	621	HNMLKTVYSDVENPHLMGWDYPK
Peptide 24	644	648	TCCSL
Peptide 25	676	685	KPGGTSSGDA
Peptide 26	712	718	GNKIADK
Peptide 27	731	742	LYRNRDVTDFV
Peptide 28	771	772	AS
Peptide 29	798	812	KCWTETDLTKGPHEF
Peptide 30	832	832	P
Peptide 31	834	834	P
Peptide 32	847	850	IVKT
Peptide 33	871	877	KHPNQEY
Peptide 34	893	893	D
Peptide 35	910	919	DNTSRYWEPE
Peptide 36	922	928	EAMYPH


**C**

**Discontinuous B cell epitopes of RdRp**

S. No.	RdRp Residue Number	Residue Name	Propensity Score	Discotope Score
1	100	ASP	-1.118	-1.335
2	117	GLN	-3.091	-3.656
3	160	LYS	-3.513	-3.224
4	264	PRO	-2.155	-2.137
5	806	THR	-2.879	-3.008
6	819	LEU	-2.672	-3.63
7	820	VAL	-0.879	-3.538
8	821	LYS	3.032	2.453
9	822	GLN	3.022	0.259
10	823	GLY	1.98	0.027
11	824	ASP	2.13	1.885
12	825	ASP	2.327	1.369
13	826	TYR	1.589	0.371
14	873	PRO	0.749	0.088
15	874	ASN	-0.477	-2.262
16	875	GLN	-3.421	-3.258
17	911	ASN	-0.83	-1.08
18	912	THR	-1.647	-2.147
19	913	SER	-2.016	-1.784
20	919	GLU	-1.995	-2.225
21	922	GLU	-1.367	-2.704
22	923	ALA	-0.296	-1.642
23	926	THR	-1.369	-2.592
24	928	HIS	-0.061	-1.204
25	929	THR	-0.89	-2.168

**Figure 3**

(i)



(ii)

S. No.	Mutants	Type of B-cell epitope
1	K59N	Linear-continuous
2	T85I	Linear-continuous
3	K91N	Linear-continuous
4	A95V	Linear-continuous
5	M110K	Linear-continuous
6	D269N	Linear-continuous
7	E278D	Linear-continuous
8	T293I	Linear-continuous
9	H295Y	Linear-continuous
10	P323L	Linear-continuous
11	A406V	Linear-continuous
12	M463I	Linear-continuous
13	I488S	Linear-continuous
14	I536T	Linear-continuous
15	V605A	Linear-continuous
16	M608I	Linear-continuous
17	T644M	Linear-continuous
18	S647I	Linear-continuous
19	Q822H	Discontinuous epitope
20	T848I	Linear-continuous
21	D893Y	Linear-continuous
22	S913L	Linear-continuous
23	S919L	Linear-continuous
24	P925S	Linear-continuous